HY

Hyperfine, Inc.

HYPRHealthcareNASDAQ

Medical Devices · Last scanned Jul 22, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$13.6M
+5.2% YoY
Net Income
-$35.6M
+12.6% YoY
EBITDA
-$36.0M
+14.7% YoY
Free Cash Flow
-$16.8M

Scan Results

Daily timeframe
6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 15 RSI OversoldRSI 26.4, below 30, stock may be oversold
Jul 14 RSI OversoldRSI 26.1, below 30, stock may be oversold
About Hyperfine, Inc.

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. The company carries a $98.4M market cap, placing it firmly in the micro-cap category. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.

Where HYPR stands vs its 150-day and 200-day moving averages

As of the July 15, 2026 close, HYPR finished 16.80% below its 150-day moving average ($1.25) and 17.46% below its 200-day moving average ($1.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is HYPR overbought or oversold?

At the July 15, 2026 close, HYPR's RSI(14) was 26.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$98.4M
Fwd P/E-2.92
EPS$-0.40
Beta1.40
52W Change-1.9%
ROE-89.8%
Analysis

The balance sheet looks solid with $40.8M in cash comfortably exceeding the $13.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$16.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -89.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $6.8M (2022) to $13.6M (2025), reflecting a 99% increase over the period.

With cash comfortably exceeding debt, HYPR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HYPR.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms
HYPR: Hyperfine, Inc. Technical Analysis (200-Day MA, RSI, MACD) | Scanance